MICROFLUIDIC PLATFORM FOR SHEAR-LESS AEROSOLIZATION OF LIPID NANOPARTICLES FOR MESSENGER RNA INHALATION

Abstract: leveraging the extensive surface area of the lungs for gene therapy, inhalation route offers distinct advantages for delivery. clinical nebulizers that employ vibrating mesh technology are the standard choice for converting liquid medicines into aerosols. however, they have limitations when it comes to delivering mrna through inhalation, including severe damage to nanoparticles due to shearing forces. a microfluidic aerosolization platform (map) can preserves the structural and physicochemical integrity of lipid nanoparticles, enabling safe and efficient mrna delivery to the respiratory system. results demonstrated the superiority of the novel microfluidic aerosolizer over the conventional vibrating mesh nebulizer, as it avoided problems such as particle aggregation, loss of mrna encapsulation, and deformation of nanoparticle morphology. notably, aerosolized nanoparticles generated by the microfluidic aerosolization platform led to enhanced transfection efficiency across various cell lines. in vivo experiments with mice that inhaled these aerosolized nanoparticles revealed successful, lung-specific mrna transfection without observable signs of toxicity. this pioneering map represents a significant advancement for the pulmonary gene therapy, enabling precise and effective delivery of aerosolized nanoparticles.

Inventor(s): Manish Giri

CPC Classification: A61M11/042 (operated by the vapour pressure of the liquid to be sprayed or atomised {(air-humidification, e.g. "room humidifiers" )})

Search for rejections for patent application number 20250205437